Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: A single institution experience

Cukier, Moisés; Smith, Andrew; Milot, Laurent; Chu, William; Chung, Hans T.; Fenech, Darlene; Herschorn, Sender; Ko, Yoo‐Joung; Rowsell, Corwyn; Soliman, Hany; Ung, Yee C.; Wong, C. Shun

doi:10.1016/j.ejso.2012.05.001

Cited by 58 publications

(49 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Arredondo et al investigated 65 patients with LACC treated with either neoadjuvant XELOX- or FOLFOX-based chemotherapy; three patients (4.6%) had a pCR [34]. In the present study, patients with LACC were administered with neoadjuvant FOLFOX-based CCRT that resulted in a pCR rate of 26.4%, which was higher than that reported in other neoadjuvant studies (2–4.6%) [14, 33, 34]. …”

Section: Discussionmentioning

confidence: 52%

“…To date, several studies have investigated the role of neoadjuvant chemotherapy in patients with LACC; however, the benefits of combined radiotherapy and chemotherapy for primary LACC have been rarely evaluated. Only a Canadian group reported that of the total 33 patients with LACC that were treated with neoadjuvant concurrent 5-FU and radiotherapy, only one patient (3%) achieved a pCR [14]. The FOxTROT trial assessed the role of neoadjuvant chemotherapy in LACC management by evaluating the efficacy and safety of the preoperative FOLFOX-based chemotherapy in a randomized controlled manner; two patients (2%) of the neoadjuvant group reported pCRs [32].…”

Section: Discussionmentioning

confidence: 99%

“…The results were similar to our study, in which five patients achieved a pCR after neoadjuvant CCRT among the 23 patients with clinical T4 tumors. For tolerability, both neoadjuvant chemotherapy and neoadjuvant CCRT were well-tolerable in patients with LACC, but toxicity was generally higher in neoadjuvant CCRT [14, 20, 32, 33]. Therefore, clinical T4 tumors, especially unresectable mass or tumors extensively involved adjacent structures, are potential indications for neoadjuvant CCRT.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer

Huang

Yeh

et al. 2017

Radiat Oncol

View full text Add to dashboard Cite

BackgroundPatients with locally advanced colon cancer (LACC) have a relatively poor prognosis despite radical resection and adjuvant chemotherapy. This study investigated the treatment efficacy and toxicity of neoadjuvant chemoradiotherapy in patients with LACC.MethodsWe retrospectively reviewed 36 patients with LACC preoperatively treated with chemotherapy and radiotherapy. Patients were administered chemoradiotherapy, which comprised radiotherapy and neoadjuvant chemotherapy involving a 5-fluorouracil, leucovorin, and oxaliplatin regimen every 2 weeks.ResultsMedian age was 64 years (45–86 years) and median follow-up period was 23.5 months (5.0–49.1 months). Seven (19.4%) patients developed grade 3 or 4 adverse events during neoadjuvant concurrent chemoradiotherapy. Pathologic responses were not evaluated in two patients who did not undergo radical resection. Of the 34 patients who underwent surgery, nine (26.4%) achieved a pathologic complete response (pCR). The 2-year estimated overall survival and disease-free survival rates were 88.7% and 73.6%, respectively.ConclusionsOur results demonstrated that neoadjuvant chemoradiotherapy is feasible and safe. A prominent pCR rate with an acceptable toxicity profile suggests that the multimodality therapy might be a treatment option for patients with LACC.

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer

Huang

Yeh

et al. 2017

Radiat Oncol

View full text Add to dashboard Cite

show abstract

“…However, 4 patients had distant metastases in the SPS group. Cukier et al reported that 3 year overall survival and disease-free survival rate was 85.9 and 73.7%, respectively (22). López-Cano et al reported that 5-year overall disease-free survival rate was 48% (23).…”

Section: Discussionmentioning

confidence: 99%

Safety and feasibility of single‑port laparoscopic multivisceral resection for locally advanced left colon cancer

et al. 2018

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the safety and feasibility of single-port laparoscopic multivisceral resection (S-MVR) for locally advanced left colon cancer. S-MVR is a challenging technique and to the best of our knowledge this is the first report of S-MVR for left colon cancer invading or adhering to neighboring organs. A retrospective review was conducted of patients who underwent laparoscopic multivisceral resection for locally advanced left colon cancer invading or adhering to neighboring organs from January 2008 to December 2014. Short-term and long-term outcomes were analyzed between groups of patients who underwent S-MVR and multi-port laparoscopic multivisceral resection (M-MVR) retrospectively. A total of 14 patients underwent S-MVR and 15 patients underwent M-MVR. There were no significant differences between groups in terms of operative factors and postoperative complications. The length of hospital stay was significantly shorter in the S-MVR group compared with the M-MVR group (P=0.048). Three-year overall survival was 61.9% in the S-MVR group (n=14). In patients with stage II (P=0.600) and III (P=0714) disease the three-year overall and disease-free survival was 81.8 and 58.3% in the S-MVR group and 80.0 and 70% in the M-MVR groups over a median follow-up of 34 months. In conclusion, S-MVR for locally advanced left colon cancer is safe and feasible in selected patients.

show abstract

“…Careful preoperative planning and multidisciplinary approach are necessary to achieve the goal of R0 resection [ 47 ].…”

Section: Referring To Radiation Oncologymentioning

confidence: 99%

Colon Cancer

Hameed¹,

Baxter²,

Cohen³

et al. 2016

Surgical Oncology Manual

View full text Add to dashboard Cite

Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: A single institution experience

Cited by 58 publications

References 19 publications

Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer

Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer

Safety and feasibility of single‑port laparoscopic multivisceral resection for locally advanced left colon cancer

Colon Cancer

Contact Info

Product

Resources

About